{
    "clinical_study": {
        "@rank": "68944", 
        "arm_group": [
            {
                "arm_group_label": "MDT-10013", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive MDT-10013."
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects will receive standard of care."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety of MDT-10013 in men and\n      women 18 to 80 years of age who are undergoing bunionectomy. The primary objective is to\n      determine the analgesic efficacy of MDT-10013 compared with standard of care in the\n      treatment of acute postoperative pain after subjects undergo bunionectomy."
        }, 
        "brief_title": "A Study of MDT-10013 in the Treatment of Acute Postoperative Pain Following Bunionectomy", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Postoperative Pain", 
        "condition_browse": {
            "mesh_term": "Pain, Postoperative"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Is male or female aged 18 to 80 years.\n\n          2. Has a body mass index from 18 kg/m2 to 40 kg/m2.\n\n          3. Is scheduled to undergo primary, unilateral, first metatarsal bunionectomy (osteotomy\n             and internal fixation) with no additional collateral procedures.\n\n          4. Is classified by American Society of Anesthesiologists Physical Status Classification\n             System as Class I or II.\n\n          5. Must meet the following criteria if female:\n\n               -  Is of non-childbearing potential, defined as any woman who has undergone\n                  surgical sterilization or is more than 2 years postmenopausal\n\n               -  If of childbearing potential, may be enrolled on the condition that results of a\n                  pregnancy test are negative at baseline (at Screening and before surgery) and\n                  that she is routinely using an effective method of birth control with a low\n                  failure rate (i.e., hormonal contraception, intrauterine device, condoms in\n                  combination with a spermicidal cream, or total sexual abstinence)\n\n          6. Has read, understood, and signed the informed consent prior to study entry.\n\n          7. Is mentally competent, reliable, and cooperative to undergo all visits and procedures\n             scheduled in the study protocol and to record the required information.\n\n          8. Has medical history, physical examination, vital signs, laboratory tests, and 12-lead\n             electrocardiograms (ECGs) that are normal or without clinically relevant\n             abnormalities as per investigator's judgment.\n\n        Exclusion Criteria:\n\n          1. Is a female who is pregnant or breastfeeding.\n\n          2. Is not indicated for surgery because of an inflammatory process or risk of infection\n             or delayed wound healing (e.g., autoimmune disorder).\n\n          3. Has a history of allergy or hypersensitivity to the components in the investigational\n             product or to the opioid medication (oxycodone).\n\n          4. Before surgery, has current orthostatic hypotension (defined as systolic blood\n             pressure decrease of at least 20 mm Hg or a diastolic blood pressure decrease of at\n             least 10 mm Hg or an increase in heart rate by 20 beats per minute within 3 minutes\n             of sitting up or standing).\n\n          5. Has severe asthma, defined as requiring frequent or ongoing treatment to control\n             symptoms. Exercise-induced asthma or mild asthma not requiring ongoing treatment may\n             not be exclusionary at the discretion of the investigator.\n\n          6. Has a current gastrointestinal disorder associated with bleeding, a history of such a\n             disorder, or gastrointestinal inflammatory diseases as Crohn's disease or ulcerative\n             colitis.\n\n          7. Has any clinically significant cardiovascular condition as evidenced by physical\n             examination, medical history, and/or baseline ECG.\n\n          8. Has evidence of bradycardia as shown by heart rate of <50 beats per minute via\n             screening ECG.\n\n          9. Has a known infection with human immunodeficiency virus, hepatitis B virus, or\n             hepatitis C virus.\n\n         10. Has a chronic pain condition that may interfere with the subject's assessment of pain\n             postoperatively, as determined by the investigator.\n\n         11. Has any poorly controlled or serious medical conditions, psychiatric illnesses, or\n             clinically significant laboratory values that, in the opinion of the investigator,\n             could compromise the safety of the subject or the scientific integrity of the study\n             (e.g., uncontrolled hypertension, autoimmune disease, or clinically relevant symptoms\n             of thyroid dysfunction).\n\n         12. Has presence or history of local or systemic malignant disease in the past 5 years\n             (history of basal cell carcinoma will be allowed).\n\n         13. Has impaired renal function (creatinine >1.5 times upper limit of normal).\n\n         14. Has chronic impairment liver function (aspartate aminotransferase or alanine\n             aminotransferase >3 times upper limit of normal).\n\n         15. Has insulin-dependent diabetes or uncontrolled diabetes mellitus (glycosylated\n             hemoglobin >7%).\n\n         16. Has leukopenia (<3500 leukocytes/\u03bcL).\n\n         17. Has current treatment with any of the following medications:\n\n               1. Systemic corticosteroids (intranasal/inhaled steroids are acceptable).\n\n               2. Immunosuppressant therapy to treat autoimmune diseases (e.g., rheumatoid\n                  arthritis, multiple sclerosis, myasthenia gravis, systemic lupus erythematosus,\n                  sarcoidosis, focal segmental glomerulosclerosis, Crohn's disease, Behcet's\n                  Disease, pemphigus, and ulcerative colitis).\n\n               3. Oral or topical products that contain clonidine (e.g., Catapres).\n\n               4. Herbal supplements that contain yohimbine.\n\n               5. Anticoagulant/antiplatelet therapy (prophylactic aspirin at 81 mg/day is\n                  acceptable). If applicable, aspirin therapy should be held before and after the\n                  study procedure on the basis of the investigator's discretion.\n\n               6. Antiepileptic drugs, antipsychotics, tricyclic antidepressants, monoamine\n                  oxidase inhibitors, lithium, and sulfonamides.\n\n               7. Calcium channel blocker, digoxin, or beta-adrenergic blockers.\n\n         18. Has chronic use of opioids (including tramadol), defined as use 20 out of the last 30\n             days before study screening.\n\n         19. Has a history of or current diagnosis of epilepsy.\n\n         20. Has a known or suspected history of drug or alcohol abuse (as determined by the\n             investigator).\n\n         21. Is judged by the investigator not to be a suitable candidate for study treatment and\n             pain relief medication on the basis of medical history, concomitant medication, and\n             concurrent systemic disease.\n\n         22. Is not stabilized on the following medications for at least 8 weeks prior to dosing:\n             selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake\n             inhibitors (SNRIs).\n\n         23. Is unable to refrain from taking nonsteroidal anti inflammatory drugs (NSAIDs) or\n             opioids within the 24-hour period prior to surgery.\n\n         24. Has participated in any other clinical trial in the 4 weeks prior to Screening.\n\n         25. Experiences any surgical complication that, in the opinion of the investigator,\n             precludes implantation of MDT-10013."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "144", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 26, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02077140", 
            "org_study_id": "P13-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "MDT-10013", 
                "intervention_name": "MDT-10013", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Standard of Care", 
                "intervention_name": "Standard of care for pain", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85027"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78705"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase II, Dose-escalating, Randomized, Double-blind, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetic Profile of MDT-10013 Versus Standard of Care in the Treatment of Acute Postoperative Pain Following Bunionectomy", 
        "other_outcome": {
            "measure": "Pharmacokinetic (PK) parameters of MDT-10013 including, but not limited to Cmax, Tmax, and AUC", 
            "safety_issue": "No", 
            "time_frame": "up to 10 days"
        }, 
        "overall_contact": {
            "email": "msbkclinicalresearch@medtronic.com", 
            "last_name": "Medtronic Clinical", 
            "phone": "1800-876-3133", 
            "phone_ext": "6068"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Summed pain intensity (calculated as a time-weighted average) by using an 11-point numeric rating scale (NRS) (0 to 10) scale over 1 to 48 hours (SPI-48).", 
            "measure": "Summed pain intensity over 1- 48 hours (SPI-48)", 
            "safety_issue": "No", 
            "time_frame": "up to 48 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02077140"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Summed pain intensity scores", 
                "safety_issue": "No", 
                "time_frame": "up to 96hrs"
            }, 
            {
                "measure": "Total use of opioid  analgesia", 
                "safety_issue": "No", 
                "time_frame": "up to 96 hours"
            }, 
            {
                "measure": "Time to first use of opioid  analgesia", 
                "safety_issue": "No", 
                "time_frame": "up to 96 hours"
            }, 
            {
                "description": "Subject's satisfaction with study treatment as measured by a 5-point categorical scale where 0 = poor, 1 = fair, 2 = good, 3 = very good, and 4 = excellent", 
                "measure": "Subject's satisfaction with study treatment", 
                "safety_issue": "No", 
                "time_frame": "up to 72 hours"
            }
        ], 
        "source": "Medtronic Spinal and Biologics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medtronic Spinal and Biologics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}